

AMENDMENT

In the Specification:

After page 7, please insert the Abstract that accompanies this Amendment.

In the Claims:

Please amend the claims as follows:

a¹

2. (Amended) The method according to claim 1 wherein the compound is N-[2-Hydroxy-4-cyanophenyl]-N'-[2-bromophenyl] urea, or N-[2-Hydroxy-4-nitrophenyl]-N'-(2-bromophenyl)urea or a pharmaceutically acceptable salt thereof.

4. (Amended) A method of inhibiting or blocking T-cell mediated chemotaxis in a patient in need thereof, which method comprises administering to said patient an effective amount of a compound which binds the CXCR2 receptor.

a²

5. (Amended) The method of according to claim 4 wherein the compound is N-[2-Hydroxy-4-cyanophenyl]-N''-[2-bromophenyl] urea, or N-2[-Hydroxy-4-nitrophenyl]-N'-(2-bromophenyl) urea or a pharmaceutically acceptable salt thereof.

REMARKS

Objections to the Oath/Declaration

The Examiner indicates that the Declaration filed by the Applicant on March 03, 2001, is defective because it bears an incorrect filing date. Applicant apologizes for this inadvertent error, which was made without deceptive intent. In response, Applicant files herewith a corrected Declaration.

Objections to the Specification

The Examiner indicates that the specification does not contain an abstract of the disclosure as required by 37 C.F.R. § 1.72(b). Applicant apologizes for this inadvertent error, and provide herewith an abstract on a separate sheet as required.

Objections to the Claims

Claims 2, 4 and 5 are objected to for several informalities. Applicant has amended the claims in order to address the Examiner's objections.